Main page content

Displaying results 1 - 10 of 10
Publication ID: PEP23-07-03-001
Published:

An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.

Publication ID: PEP22-07-03-002
Published:

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

Publication ID: PEP22-07-03-001
Published:

An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

Publication ID: SMA18-5093
Published:

The report discusses Medicaid coverage of FDA-approved medications for treatment of alcohol and opioid use disorders, limitations on coverage (such as prior authorization requirements), background on federal laws and policies and innovative practices and policies at the state level.

Publication ID: SMA16-4999
Published:

The report highlights the need for HIV treatment providers to address behavioral health concerns with HIV. The report urges providers to start with screening for mental health and substance use disorders, and offers strategies for providers to implement screening practices.

Publication ID: SMA16-4990
Published:

This executive summary of the Surgeon General's Report on Alcohol, Drugs, and Health addresses alcohol, illicit drugs, and prescription drug misuse in the United States. Chapters of the report cover neurobiology, prevention, treatment, recovery, health systems integration, and recommendations for the future.

Publication ID: SMA16-4991
Published:

This Surgeon General's Report on Alcohol, Drugs, and Health addresses the prevalence of alcohol, illicit drugs, and prescription drug misuse in the United States. Chapters of the report cover neurobiology, prevention, treatment, recovery, health systems integration, and recommendations for the future.

Publication ID: SMA15-4929
Published:

This report examines the opportunities and challenges associated with municipal court diversion for people living with mental illness and substance use disorder conditions. It outlines elements for effective diversion, recovery-based engagement strategies, and proportional response.

Publication ID: SMA14-4854
Published:

This report presents information about Medicaid coverage of medication-assisted treatment for opioid and alcohol dependence. It covers treatment effectiveness and cost effectiveness. The report also offers examples of innovative approaches in Vermont, Massachusetts, and Maryland.

Publication ID: SMA12-4724
Published:

This report presents the key principles and core expectations of the State Epidemiological Outcomes Workgroups. The workgroups are designed to use data to inform and enhance state and community decisions regarding substance use and mental illness prevention programs.